{"filing":{"accession_number":"0001104659-26-069251","cik":"0001390478","ticker":"SLS","company_name":"SELLAS Life Sciences Group, Inc.","form":"8-K","filing_date":"2026-06-02","report_date":null,"primary_document":"tm2616601d1_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1390478/000110465926069251/tm2616601d1_8k.htm"},"events":[{"id":7384,"run_id":6488,"accession_number":"0001104659-26-069251","anchor_item_number":"8.01","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.65,"summary":"The disclosure reports receipt of approximately $28.7 million in warrant exercise proceeds in April-May 2026, increasing cash from $107.1 million to approximately $135.8 million, and notes 196.6 million shares outstanding as of June 2, 2026. While warrant exercises are a form of dilutive issuance, the filing emphasizes the cash proceeds and liquidity position rather than the equity issuance mechanics, and does not clearly indicate this was a private placement or PIPE transaction. The material cash infusion and updated share count are relevant to investor assessment, but the event does not fit cleanly into the dilutive_issuance category (which typically covers unregistered private placements) or any other specific taxonomy item.","company_name":"SELLAS Life Sciences Group, Inc.","ticker":"SLS","filing_date":"2026-06-02","form":"8-K","submitted_at":null,"items":[{"id":3463,"accession_number":"0001104659-26-069251","item_number":"8.01","item_title":null,"event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.65,"reasoning":"The disclosure reports receipt of approximately $28.7 million in warrant exercise proceeds in April-May 2026, increasing cash from $107.1 million to approximately $135.8 million, and notes 196.6 million shares outstanding as of June 2, 2026. While warrant exercises are a form of dilutive issuance, the filing emphasizes the cash proceeds and liquidity position rather than the equity issuance mechanics, and does not clearly indicate this was a private placement or PIPE transaction. The material cash infusion and updated share count are relevant to investor assessment, but the event does not fit cleanly into the dilutive_issuance category (which typically covers unregistered private placements) or any other specific taxonomy item.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-03T02:10:07.181348+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":3463,"accession_number":"0001104659-26-069251","item_number":"8.01","item_title":null,"event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.65,"reasoning":"The disclosure reports receipt of approximately $28.7 million in warrant exercise proceeds in April-May 2026, increasing cash from $107.1 million to approximately $135.8 million, and notes 196.6 million shares outstanding as of June 2, 2026. While warrant exercises are a form of dilutive issuance, the filing emphasizes the cash proceeds and liquidity position rather than the equity issuance mechanics, and does not clearly indicate this was a private placement or PIPE transaction. The material cash infusion and updated share count are relevant to investor assessment, but the event does not fit cleanly into the dilutive_issuance category (which typically covers unregistered private placements) or any other specific taxonomy item.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-03T02:10:07.181348+00:00","company_name":"SELLAS Life Sciences Group, Inc.","ticker":"SLS","filing_date":"2026-06-02"}]}